Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Conditions
Brief summary
This phase II trial is studying how well giving rituximab and cyclophosphamide together with bortezomib and dexamethasone (R-CyBor-D) works in treating patients with relapsed or refractory low-grade follicular lymphoma, Waldenstrom macroglobulinemia, or mantle cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab and bortezomib together with combination chemotherapy may kill more cancer cells.
Detailed description
PRIMARY OBJECTIVES: I. To assess tumor response to R-CyBor-D in patients with relapsed follicular (Gr 1 or 2), mantle cell, marginal zone lymphomas, small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and lymphoplasmacytic (Waldenstrom's macroglobulinemia) lymphoma. SECONDARY OBJECTIVES: I. To evaluate overall survival, progression-free survival, duration of response, and time to treatment failure of patients receiving R-CyBor-D. II. To describe the adverse event profile (using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] v 3.0) of R-CyBor-D. III. To evaluate quality of life for patient reported neurotoxicity using the Gynecologic Oncology Group's Functional Assessment of Cancer Therapy (FACT/GOG) neurotoxicity questionnaire, version 4.0. OUTLINE: Patients receive rituximab intravenously (IV) on day 1and cyclophosphamide orally (PO), bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3-6 months for up to 3 years.
Interventions
DRUGBortezomib
Given IV
BIOLOGICALRituximab
Given IV
DRUGCyclophosphamide
Given PO
DRUGDexamethasone
Given PO
OTHERQuestionnaire Administration
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
OTHERQuality-of-Life Assessment
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Sponsors
National Cancer Institute (NCI)
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological confirmation of relapsed or refractory follicular Grades 1 or 2 lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, or lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia/WM) by biopsy ≤ 6 months prior to registration * NOTE: MCL diagnosis should be confirmed by cyclin D1 staining or fluorescence in situ hybridization (FISH) (t(11;14)) * Measurable disease by computed tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI) scans with lymph nodes ≥2.0 cm in at least one dimension or tumor cells in the blood ≥ 5 x10\^9/L * NOTE: Lymphoplasmacytic lymphoma (WM) patients without lymphadenopathy must have 1.) \>10% lymphocytes, lymphoplasmacytic cells or plasma cells on a bone marrow aspirate/biopsy, and 2.) quantitative IgM ≥ 400mg/dL * Expected survival \> 3 months * ECOG Performance Status (PS) 0, 1 or 2 * Absolute Neutrophil Count ≥ 1200 * Platelet ≥ 75000 * Hemoglobin ≥ 8.0 g/dL * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * Alkaline phosphatase ≤ 3 x ULN * Aspartate aminotransferase (AST) ≤ 3 x ULN * Creatinine ≤ 1.5 x ULN * Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of VELCADE (bortezomib), or agree to completely abstain from heterosexual intercourse * Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Willingness to return to Mayo Clinic institution for follow-up * Negative serum pregnancy test done \<7 days prior to registration, for women of childbearing potential only * Willingness to complete questionnaires by themselves or with assistance
Exclusion criteria
* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant women -- confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women; * Nursing women; * Men or women of childbearing potential who are unwilling to employ adequate contraception * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse event of the prescribed regimen * Patients known to be human immunodeficiency virus (HIV) positive * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Diagnosed or treated for another malignancy ≤ 3 years prior to registration, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy * NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer * Patient has received other investigational drugs ≤ 14 days prior to registration * Patient has hypersensitivity to bortezomib, boron or mannitol * Myocardial infarction ≤ 6 months prior to registration or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities * NOTE: Prior to study entry, any electrocardiogram (ECG) abnormality at Screening has to be documented by the investigator as not medically relevant * Previous cancer therapy, hormonal therapy and surgery \< 4 weeks prior to registration * Patient has ≥ Grade 2 peripheral neuropathy * Radiation therapy within 3 weeks before randomization * Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Responses (Complete Response or Partial Response) | up to 12 cycles | A response is defined to be a Complete Response (CR) or Partial Response (PR) noted as the objective status on any evaluation (i.e., best response). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. A confidence interval for the true success proportion will be calculated according to the properties of the binomial distribution. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Up to 3 years from registration | Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. |
| Progression-free Survival | Up to 3 years from registration | Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression or death, whichever occurs first. Progression is defines as having any new lesion or increase by 50% of previously involved sites from nadir. The distribution of progression-free survival time will be estimated using the method of Kaplan-Meier. |
| Duration of Response | Up to 3 years from registration | Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented. MR for Waldenstrom lymphoma will not be included as a response. Median duration of response and the confidence interval for the median duration will be computed. |
| Time to Treatment Failure | Up to 3 years from registration | Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier. |
| Adverse Events | up to 12 cycles (28 days per cycle) of treatment | Adverse events were assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 after each cycle of treatment. The maximum grade for each type of adverse event were recorded for each patient, and frequency tables were reviewed to determine patterns. For this endpoint, the number of patients receiving a Grade 3, Grade 4, or Grade 5 as their highest reported grade regardless of attribution are reported. A full list of adverse events are reported in the Adverse Events section of this report. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment Rituximab 375 mg/m2 IV on day 1\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\> Dexamethasone 40 mg PO on days 1, 8, 15, 22 | 21 |
| Total | 21 |
Baseline characteristics
| Characteristic | Treatment |
|---|---|
| Age, Continuous | 69 years |
| Region of Enrollment United States | 21 participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 21 / 21 |
| serious Total, serious adverse events | 7 / 21 |
Outcome results
Primary
Proportion of Responses (Complete Response or Partial Response)
A response is defined to be a Complete Response (CR) or Partial Response (PR) noted as the objective status on any evaluation (i.e., best response). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. A confidence interval for the true success proportion will be calculated according to the properties of the binomial distribution.
Time frame: up to 12 cycles
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment | Proportion of Responses (Complete Response or Partial Response) | Complete Response (CR) | 19.0 percentage of participants |
| Treatment | Proportion of Responses (Complete Response or Partial Response) | Partial Response (PR) | 42.9 percentage of participants |
Secondary
Adverse Events
Adverse events were assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 after each cycle of treatment. The maximum grade for each type of adverse event were recorded for each patient, and frequency tables were reviewed to determine patterns. For this endpoint, the number of patients receiving a Grade 3, Grade 4, or Grade 5 as their highest reported grade regardless of attribution are reported. A full list of adverse events are reported in the Adverse Events section of this report.
Time frame: up to 12 cycles (28 days per cycle) of treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment | Adverse Events | Grade 3 | 19 participants |
| Treatment | Adverse Events | Grade 4 | 8 participants |
| Treatment | Adverse Events | Grade 5 | 0 participants |
Secondary
Duration of Response
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented. MR for Waldenstrom lymphoma will not be included as a response. Median duration of response and the confidence interval for the median duration will be computed.
Time frame: Up to 3 years from registration
Population: Thirteen patients achieved a CR or a PR and are included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment | Duration of Response | 25.9 months |
Secondary
Overall Survival
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time frame: Up to 3 years from registration
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment | Overall Survival | 54.8 months |
Secondary
Progression-free Survival
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression or death, whichever occurs first. Progression is defines as having any new lesion or increase by 50% of previously involved sites from nadir. The distribution of progression-free survival time will be estimated using the method of Kaplan-Meier.
Time frame: Up to 3 years from registration
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment | Progression-free Survival | 11.6 months |
Secondary
Time to Treatment Failure
Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.
Time frame: Up to 3 years from registration
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment | Time to Treatment Failure | 6.6 months |